RECRUITING

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.

Official Title

Quantifying Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Quick Facts

Study Start:2023-09-15
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05406232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients \>= 18 years of age with biopsy proven invasive breast cancer
  2. * Breast cancer that appears to be superficially accessible to a tumor punch biopsy
  3. * Patients thought to derive clinical benefit from palliative RT to the breast/chestwall
  4. * In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT
  1. * A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered
  2. * Pregnancy
  3. * Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies
  4. * Receipt of immunotherapy or chemotherapy 7 days prior to start of RT

Contacts and Locations

Study Contact

Simona F Shaitelman, MD
CONTACT
(713) 563-8491
sfshaitelman@mdanderson.org

Principal Investigator

Simona F Shaitelman, MD
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Simona F Shaitelman, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-15
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2023-09-15
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Carcinoma
  • Invasive Breast Carcinoma